Scynexis Inc (SCYX) Stock Price, Quote & News

Company Profile

SCYNEXIS, Inc., a biotechnology company, develops medicines to overcome and prevent difficult-to-treat and drug-resistant infections in the United States. It offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis (VVC) and recurrent VVC. The company's lead product candidate is Ibrexafungerp, a drug for the treatment of invasive candidiasis and/or candidemia, refractory invasive fungal infections, invasive aspergillosis, VVC, and recurrent VVC. It also develops SCY-247 to t...

Industry: Drug Manufacturers - Specialty & Generic

Sector: Healthcare

Phone: 201 884 5485

Website: www.scynexis.com

Address:

1 Evertrust Plaza, 13th Floor, Jersey City, United States

sam2680 Jul. 11 at 5:54 PM

$SCYX just not today!

0 · Reply

pjinvestmentco Jul. 11 at 4:27 PM

$SCYX Lemuel has offered to buy Scynexis for $75 in cash and 6 cinnamon rolls for the Scynexis Board of Directors from Cinnabon

1 · Reply

dgoumasmd Jul. 11 at 1:18 PM

$SCYX it continues to bewilder me why the stock does not pick up traction article here indicating fungal infections are getting more difficult to treat. They have a medication that can treat them.

1 · Reply

dgoumasmd Jul. 11 at 1:17 PM

$SCYX

0 · Reply

pjinvestmentco Jul. 10 at 1:06 PM

$SCYX I think Joe Biden has talked more then David in the last 4 years

0 · Reply

stocks_up1 Jul. 9 at 8:32 PM

$SCYX - Does anyone know when the next batch of warrants expire?

1 · Reply

Stmkr Jul. 9 at 7:17 PM

$SCYX Best case scenario here is a SCY-247 partnership. I don't see anything else with potential. GSK clearly does not care to commercialize ibrexafungerp

0 · Reply

whob007 Jul. 9 at 7:15 PM

$SCYX stock acting like GSK is being a bitch

0 · Reply

Stmkr Jul. 9 at 7:12 PM

$SCYX "While at this time it is too early to say how this disagreement may be resolved, GSK has reiterated its commitment to continued collaboration regarding other aspects of the GSK License Agreement including with respect to the commercialization of BREXAFEMME for the VVC and rVVC indications." No news here either...

1 · Reply

pantarei Jul. 9 at 7:02 PM

$SCYX management simply disappeared with no updates on brexa commercialization status and GSK question. Embarassing.

0 · Reply

SCYNEXIS Resumes Patient Dosing in Phase 3 MARIO Study

Mar 12, 2025, 5:08 PM EDT - 4 months ago

SCYNEXIS Reports Full Year 2024 Financial Results and Provides Corporate Update

Nov 6, 2024, 4:30 PM EST - 8 months ago

SCYNEXIS Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Oct 10, 2024, 8:00 AM EDT - 9 months ago

SCYNEXIS to Participate in the 2024 Maxim Healthcare Virtual Summit

Oct 3, 2024, 8:00 AM EDT - 10 months ago

SCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at IDWeek 2024

Aug 27, 2024, 8:00 AM EDT - 11 months ago

SCYNEXIS to Participate in H. C. Wainwright 26th Annual Global Investment Conference

Aug 8, 2024, 4:30 PM EDT - 1 year ago

SCYNEXIS Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Jul 23, 2024, 7:00 AM EDT - 1 year ago

SCYNEXIS to Receive $10 Million Milestone Payment from GSK Triggered by Delivery of Completed FURI, CARES and NATURE Clinical Study Reports

May 8, 2024, 4:30 PM EDT - 1 year ago

SCYNEXIS Reports First Quarter 2024 Financial Results and Provides Corporate Update

Apr 30, 2024, 4:05 PM EDT - 1 year ago

SCYNEXIS Presented Preclinical Data on Second Generation Fungerp SCY-247 at the Congress of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID Global, Formerly ECCMID)

Apr 9, 2024, 4:05 PM EDT - 1 year ago

SCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at the 34th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)

Apr 2, 2024, 10:04 AM EDT - 1 year ago

Scynexis: Update Following Restructuring Of GSK Deal

Mar 28, 2024, 4:01 PM EDT - 1 year ago

SCYNEXIS Reports Full Year 2023 Financial Results and Provides Corporate Update

Jan 29, 2024, 5:15 PM EST - 1 year ago

SCYNEXIS Presented Preclinical Data on Second Generation Fungerp SCY-247 against Mucormycosis at the 11th Advances Against Aspergillosis and Mucormycosis Conference

Jan 8, 2024, 4:00 AM EST - 1 year ago

FINAL DEADLINE TODAY: The Schall Law Firm Encourages Investors in SCYNEXIS, Inc. with Losses to Contact the Firm

Jan 5, 2024, 8:30 AM EST - 1 year ago

SCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at the 11th Advances Against Aspergillosis and Mucormycosis Conference, January 25 – 27, in Milan, Italy

Jan 4, 2024, 7:00 AM EST - 1 year ago

JANUARY 8 FINAL DEADLINE: The Schall Law Firm Encourages Investors in SCYNEXIS, Inc. with Losses to Contact the Firm

Dec 29, 2023, 4:00 AM EST - 1 year ago

FINAL DEADLINE IMMINENT: The Schall Law Firm Encourages Investors in SCYNEXIS, Inc. with to Contact the Firm

Dec 28, 2023, 9:00 AM EST - 1 year ago

SCYNEXIS INVESTOR DEADLINE APPROACHING: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $25,000 In Scynexis To Contact Him Directly To Discuss Their Options

Dec 22, 2023, 7:00 AM EST - 1 year ago

IMPORTANT DEADLINE REMINDER: The Schall Law Firm Encourages Investors in SCYNEXIS, Inc. with Losses to Contact the Firm

Dec 21, 2023, 8:00 AM EST - 1 year ago

DEADLINE ACTION NOTICE: The Schall Law Firm Encourages Investors in SCYNEXIS, Inc. with Losses of $100,000 to Contact the Firm

Dec 19, 2023, 5:30 AM EST - 1 year ago

INVESTOR ACTION NOTICE: The Schall Law Firm Encourages Investors in SCYNEXIS, Inc. with Losses to Contact the Firm

Dec 18, 2023, 6:46 PM EST - 1 year ago

Scynexis: Stock Has Been Punished Enough: GSK Partnership, Future Revenue Potential And 2-Year Cash Runway Warrant A 'Buy'

Dec 18, 2023, 6:15 AM EST - 1 year ago

DEADLINE ACTION NOTICE: The Schall Law Firm Encourages Investors in SCYNEXIS, Inc. with Losses to Contact the Firm

Dec 13, 2023, 7:00 AM EST - 1 year ago

FINAL DEADLINE APPROACHING: The Schall Law Firm Encourages Investors in SCYNEXIS, Inc. with Losses to Contact the Firm

Dec 8, 2023, 5:00 AM EST - 1 year ago

IMPORTANT DEADLINE REMIDNER: The Schall Law Firm Encourages Investors in SCYNEXIS, Inc. with Losses to Contact the Firm

Dec 6, 2023, 7:00 AM EST - 1 year ago

FINAL DEADLINE REMINDER: The Schall Law Firm Encourages Investors in SCYNEXIS, Inc. with Losses to Contact the Firm

Dec 4, 2023, 7:00 AM EST - 1 year ago

IMPORTANT DEADLINE REMINDER: The Schall Law Firm Reminds Investors in SCYNEXIS, Inc. with Losses to Contact the Firm

Dec 1, 2023, 6:00 AM EST - 1 year ago

IMPORTANT DEADLINE REMINDER: The Schall Law Firm Encourages Investors in SCYNEXIS, Inc. with Losses of $100,000 to Contact the Firm

Nov 30, 2023, 8:30 AM EST - 1 year ago

SCYNEXIS INVESTOR DEADLINE APPROACHING: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Scynexis To Contact Him Directly To Discuss Their Options

Nov 29, 2023, 7:50 PM EST - 1 year ago

IMPORTANT DEADLINE NOTICE: The Schall Law Firm Encourages Investors in SCYNEXIS, Inc. with Losses of $100,000 to Contact the Firm

Nov 22, 2023, 11:45 PM EST - 1 year ago

INVESTOR DEADLINE NOTICE: The Schall Law Firm Encourages Investors in SCYNEXIS, Inc. with Losses of $100,000 to Contact the Firm

Nov 21, 2023, 7:00 AM EST - 1 year ago

IMPORTANT JANUARY DEADLINE: The Schall Law Firm Encourages Investors in SCYNEXIS, Inc. with Losses of $100,000 to Contact the Firm

Nov 19, 2023, 11:45 PM EST - 1 year ago

INVESTOR ACTION NOTICE: The Schall Law Firm Encourages Investors in SCYNEXIS, Inc. with Losses of $100,000 to Contact the Firm

Nov 17, 2023, 11:15 AM EST - 1 year ago

IMPORTANT INVESTOR NOTICE: The Schall Law Firm Encourages Investors in SCYNEXIS, Inc. with Losses of $100,000 to Contact the Firm

Nov 15, 2023, 1:15 PM EST - 1 year ago

SCYX STOCKHOLDERS: Contact Robbins LLP for Information About Your Rights Against Scynexis, Inc.

Nov 13, 2023, 5:17 PM EST - 1 year ago

SCYNEXIS Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Oct 24, 2023, 8:00 AM EDT - 1 year ago

SCYNEXIS Presents New Preclinical Data on Second Generation Fungerp SCY-247 at the 11th Congress on Trends in Medical Mycology (TIMM)

Oct 6, 2023, 5:20 PM EDT - 1 year ago

The Law Offices of Frank R. Cruz Announces Investigation of SCYNEXIS, Inc. (SCYX) on Behalf of Investors

sam2680 Jul. 11 at 5:54 PM

$SCYX just not today!

0 · Reply

pjinvestmentco Jul. 11 at 4:27 PM

$SCYX Lemuel has offered to buy Scynexis for $75 in cash and 6 cinnamon rolls for the Scynexis Board of Directors from Cinnabon

1 · Reply

dgoumasmd Jul. 11 at 1:18 PM

$SCYX it continues to bewilder me why the stock does not pick up traction article here indicating fungal infections are getting more difficult to treat. They have a medication that can treat them.

1 · Reply

dgoumasmd Jul. 11 at 1:17 PM

$SCYX

0 · Reply

pjinvestmentco Jul. 10 at 1:06 PM

$SCYX I think Joe Biden has talked more then David in the last 4 years

0 · Reply

stocks_up1 Jul. 9 at 8:32 PM

$SCYX - Does anyone know when the next batch of warrants expire?

1 · Reply

Stmkr Jul. 9 at 7:17 PM

$SCYX Best case scenario here is a SCY-247 partnership. I don't see anything else with potential. GSK clearly does not care to commercialize ibrexafungerp

0 · Reply

whob007 Jul. 9 at 7:15 PM

$SCYX stock acting like GSK is being a bitch

0 · Reply

Stmkr Jul. 9 at 7:12 PM

1 · Reply

pantarei Jul. 9 at 7:02 PM

$SCYX management simply disappeared with no updates on brexa commercialization status and GSK question. Embarassing.

0 · Reply

Stmkr Jul. 9 at 7:01 PM

$SCYX "Pursuant to the GSK License Agreement, the Company is responsible for conducting the MARIO study. The GSK License Agreement provides that certain material changes to the study, including termination, require mutual written agreement of both parties. The Company has not provided such agreement. The GSK License Agreement only provides GSK with a unilateral termination right in the event that dosage of the first new patient in MARIO had not occurred by a particular date. The date was set as April 26, 2025, subject to automatic extension of up to two months, or June 26, 2025, if the implementation of additional in process control method validation was included in the amended IND or required by GSK, resulting in additional time in the manufacturing process." Not clear to me if the conditions for the 2 montha extension are satisfied. New patients were dosed in May. Anyone?

1 · Reply

pjinvestmentco Jul. 9 at 5:29 PM

$SCYX @LemuelPitkin has accepted a position at Scynexis as the Chief Marketing and Revenue Officer. Primary responsibility is to achieve $1000 in product sales

1 · Reply

SnapCrackleStop Jul. 9 at 2:56 PM

$SCYX $64K question Why is $GSK not marketing a drug they essentially paid $90MM for? $

1 · Reply

LemuelPitkin Jul. 8 at 8:39 PM

$SCYX When will Mario(NCT05178862) complete? Grok Best Guess: For a global study with 220 patients, enrolling 10–20 patients per month across multiple sites is reasonable. Balancing the enrollment pace (15/month), follow-up, and analysis timelines, the MARIO trial is most likely to complete around October 2026, rounded to the nearest month. This accounts for enrolling the remaining 165 patients by April 2026, a 3-month follow-up, and 3 months for data analysis.Final Answer: October 2026, --- And Phase1 Scy-247 trial?: Based on SCYNEXIS’s guidance and the trial’s design, the Phase 1 trial for SCY-247 is most likely to complete around September 2025, to the nearest month. This accounts for dosing completion in mid-2025 and data reporting by the end of Q3 2025.

0 · Reply

stocks_up1 Jul. 6 at 8:01 PM

$SCYX - I think we get some good news this week.

3 · Reply

WarrenDouglasTrader Jul. 3 at 7:46 PM

$SCYX Im back in. I must be insane

1 · Reply

LemuelPitkin Jul. 1 at 9:47 PM

$SCYX The 8- k report has been issued to shareholders. What does it say? Based on the votes, this board of directors and the officers of this company are wildly popular. Chew on that. There are several people here who are convinced that the board and the officers are incompetent. Based on the 8-K, that viewpoint represents one in 20 shareholders. To the naysayers here, I think this is a moment for you to reflect upon why you are so out of sync with the majority of shareholders: What is it that the majority of shareholders see that you don't? Why are they happy with our progress as a company and you are not? I'm just going to say what I think. My impression is that the negative people here are solely obsessed with the stock price irregardless of all the other factors and things of importance down the line. These are people with short-term demands. They cannot see the bigger picture or can't afford to see it. Scyx stock was never a get rich quick option.

1 · Reply

whob007 Jul. 1 at 8:52 PM

$SCYX I hope they are going to avoid the reverse split and 2 things seem to say they will but not in so many words 1- paying off the convertible debt, all 14 million, and avoiding dilution 2. Recent stock option grants at a $0.74 strike: Why issue them if the BOD was considering a Reverse split? They would wait.

2 · Reply

SnapCrackleStop Jul. 1 at 4:41 PM

$SCYX This is not going to zero. No. Honestly folks. $GSK is on the hook for $30 mill. That will get paid. That one payment is greater than today’s wild market cap based on a 68cent stick price. I’m not sure but MARIO will be successful then we have SC247. Look ahead folks!!!! This knee jerk reaction to a delisting is utterly ridiculous. They have at least 6 months to regain compliance. When that $30 mill $GSK payment comes in this price will have been a “woulda”, “coulda”, “shoulda” moment. Overweight and not dieting!!! $$$

1 · Reply

chotis Jul. 1 at 2:35 PM

$SCYX is this going to zero?

2 · Reply

pjinvestmentco Jul. 1 at 12:54 PM

$SCYX you can buy 2 shares of SCYX for 1 pack of Bubble yum

0 · Reply

pjinvestmentco Jul. 1 at 12:52 PM

$SCYX 65 cents today and maybe lower

0 · Reply

Market Cap	27.43M
Revenue (ttm)	3.75M
Net Income (ttm)	-21.29M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-567.73%
Debt to Equity Ratio	0.00

Volume	118,900
Avg Vol	152,984
Day's Range	N/A - N/A
Shares Out	39.02M
Stochastic %K	48%
Beta	1.57
Analysts	Strong Sell
Price Target	$4.67